How European Federation of Pharmaceutical Industries and Associations lobbied on EU Inc
Supports, with changes
Business association · BEL
Supports the EU Inc. proposal as a strong reform to aid biopharmaceutical SMEs but wants broad implementation and complementary measures to ensure full harmonisation and capital mobilisation.
1 submission to the Commission · declared EU lobbying: €6,000,000–€6,499,999 last year.
Summaries are AI-written; the quotes are theirs, checked word for word.
What they asked for
Who can use it?
Backs it
Feedback on the proposal (2026) · 24 Jun 2026
Allow all companies, especially biopharmaceutical SMEs, to use the single EU-wide corporate form to facilitate scaling up across Member States.
“At its core, the initiative would allow companies to operate under a single optional EU wide corporate framework rather than navigating 27 different national company law systems.”
Ensure company creation within 48 hours with fully digital procedures and a maximum fee of 100 euros to reduce administrative burden.
“The EU Inc. harmonised structure should also reduce administrative burden with a creation of a company within 48 hours, at a maximum of 100, with fully digital procedures.”
Implement stronger measures to mobilise long-term capital for innovative biopharmaceutical companies in Europe.
“The success of EU Inc. will also depend on stronger measures to mobilise long-term capital for innovative biopharmaceutical companies operating in Europe.”
WhoShapedIt is a thin layer on open-source packages. Star them, fork them, build your own micro.
Contextrie
star 60
Open-source context and state for AI: it keeps only what matters for the question.
In WhoShapedIt: Reads every lobby submission and position paper and each official text, cut into passages, and judges each passage against nine questions (who can use EU Inc, workers on the board, tax…), so every ask and every step is read on the passages that address it.